## Gene Summary
TBC1D1, short for TBC1 Domain Family Member 1, is a gene that encodes a protein involved in the regulation of glucose and insulin signaling pathways. It is predominantly expressed in skeletal muscle and adipose tissue. The protein product of TBC1D1 is responsible for the translocation of glucose transporter type 4 (GLUT4) to the plasma membrane, a process that is critical for glucose uptake in response to insulin stimulation. It contains a TBC (Tre-2/Bub2/Cdc16) domain, implying a role as a GTPase-activating protein, primarily influencing Rab GTPases involved in vesicular trafficking.

## Gene Drugs, Diseases, Phenotypes, and Pathways
TBC1D1 has been studied in the context of obesity, insulin resistance, and type 2 diabetes due to its role in glucose metabolism. Abnormalities or polymorphisms in this gene are thought to affect these metabolic processes, potentially leading to altered disease susceptibility. TBC1D1 interacts with several key signaling pathways, including those involved in insulin signaling and glucose transport, making it a candidate gene for studies on metabolic syndrome and diabetes-related traits. It has also been researched for its role in physical activity and energy expenditure, suggesting a broader impact on metabolic health.

## Pharmacogenetics
Research into the pharmacogenetics of TBC1D1 primarily focuses on how genetic variants within this gene may influence the risk of metabolic disorders and their response to therapies. Although specific drugs targeting TBC1D1's activity directly are not well-documented, understanding variations in this gene could help tailor treatments in diabetes, such as optimizing insulin therapy or developing new agents that enhance GLUT4 translocation. The gene's influence on muscle glucose uptake and insulin sensitivity suggests potential indirect interactions with antidiabetic drugs, although direct associations with specific pharmacological agents have yet to be fully established. Further pharmacogenetic investigations could elucidate how TBC1D1 variants affect individual responses to treatments in metabolic disease contexts.